Cascaded Dual-Targeting (WTW/TAT) Liposomes Delivery DOX for Precision Glioblastoma Treatment

DOX@WT-LIP achieves 60.74% ± 2.14 permeated dose at 480 min and improves GBM killing in a BBB/GBM co-culture using WTW/TAT dual-targeted liposomes.

• Why it matters: GBM therapy is limited by the BBB and BTB, which restrict drug movement into tumor tissue, creating a delivery bottleneck that needs sequential barrier crossing.
• What they did: The study built a dual-targeted liposomal platform (WT-LIP) carrying doxorubicin, using WTW for receptor-mediated BBB transcytosis and TAT for post-barrier penetration, then tested endothelial transport in vitro and brain/tumor delivery in orthotopic U251-luc mice.
• The result: In orthotopic U251-luc models, DiD-labeled WT-LIP increased brain/tumor accumulation (G/B = 2.16 ± 0.06), while DOX@WT-LIP inhibited tumor growth by 74.92%, improved survival, and showed comparatively reduced systemic toxicity.

AI summary of the abstract · may contain errors · not medical advice · read the paper.